In last few years, peptide therapeutics has demonstrated maturity that reflects their ability in the management of wide range of diseases.
Global Peptide Therapeutics Market & Clinical Trials Insight 2028 Report Findings:
• Global Peptide Therapeutics Market Opportunity > USD 75 billion by 2028
• Global Peptide Therapeutics Clinical Trials Insight by Company, Indication & Phase
• Peptide Therapeutics in Clinical Trials: > 800 Drugs
• Peptide Therapeutics Commercially Available In Market: > 200 Drugs
• Global Peptide Therapeutics Clinical Trials Insight By Peptide Type: Glucagon-like Peptides, Cyclic Peptides, Glycopeptides, Oligopeptides, Lipopeptides, Dipeptides, Opioid, Depsipeptides, Neuropeptides, Natriuretic, Bicyclic Peptides
Download Report Sample:
https://www.kuickresearch.com/ccformF.php?t=1650627251
In last few years, peptide therapeutics has demonstrated maturity that reflects their ability in the management of wide range of diseases. Peptide represents unique class of pharmaceutical products which have low molecular weight and possess the ability of both small molecules as well as proteins. The huge amount interest in peptide therapeutics by pharmaceutical giants and research institutions is mainly attributed to their various advantages over other available conventional therapies. Because of their small size, peptides have the ability to penetrate deeper into the target tissue and induce robust responses. Apart from this, the simplicity of manufacturing peptides has also gained a lot of interest in the pharmaceutical companies.
Since their commercial availability into the market, the cost of peptide manufacturing is decreasing continuously with the advent of new technologies. Recently scientists at Imperial College London have developed novel peptide manufacturing technology known as PEPSTAR. The technology provides an efficient way to speed up the process of peptide synthesis without compromising on quality. It has the ability to be scaled-up for commercial use and could be extended to the production of other sequence-defined polymers in a variety of applications. It is believed that PEPSTAR has the potential to significantly lower the cost of peptide drugs, thus making them widely accessible to large number of patients.
At present, more than 200 peptide drugs have been approved by regulatory bodies for the management of wide range of diseases including diabetes, cancer and HIV, with more drugs currently in development. Several modalities including peptide drug conjugate, peptide based vaccines, or small molecule drugs have been adopted by researchers which have demonstrated encouraging response. Presently, only peptide cancer vaccine is available in South Korea. Riavax (GV1001) is a peptide drug vaccine which is derived from human telomerase consisting of 16 amino acids and is indicated for the treatment of locally advanced or metastatic pancreatic cancer vaccine patients who have higher serum eotaxin levels. Apart from pancreatic cancer, researchers have also validated the role of Riavax in other therapeutic conditions including non-small cell lung cancer, breast cancer, prostate cancer, Alzheimer disease, and others. The rising activities will also boost the growth of market in forthcoming years.
The encouraging response of peptide therapeutics has motivated the further research and development activities in this domain. Currently, more than 600 clinical trials are ongoing in global peptide therapeutics market which is evaluating novel peptide therapeutics products across various chronic disorders. The global peptide therapeutics market is highly competitive in nature, with major players focused on adoption of various strategies such as product innovation, product launches, and approvals, research and development investment for advancement in peptide therapeutics, mergers and acquisitions as their developmental strategies to sustain the competitive environment of global market. For instance in 2022, Ironwood Pharmaceuticals entered into collaboration with Protagonist Therapeutics to discover novel peptides for potential development by Ironwood. The collaboration capitalizes on Protagonist's proprietary disulfide rich peptide (DRP) technology platform, and provides Ironwood with the opportunity to develop novel peptides and treatments against clinically-validated targets in therapeutic areas with significant unmet medical needs. The other key companies mentioned in the report include Novartis, Pfizer, Roche, Lonza, Takeda Pharmaceutical, Teva Pharmaceutical, Ipsen, and others.
As per our report findings, the global peptide therapeutics market is expected to surpass US$ 75 Billion by 2028. The major factor that contributes to the growth of global peptide therapeutics market include increase in prevalence of chronic diseases, surge in awareness related to use of peptide therapeutics. Furthermore, other factors such as rise in healthcare expenditure and surge in governmental support for research in the field of peptide therapeutics fuel the growth of market.
Contact:
Neeraj Chawla
Kuick Research
Research Head
neeraj@kuickresearch.com
+91-9810410366